On Friday, Candel Therapeutics Inc (CADL) stock saw a decline, ending the day at $7.54 which represents a decrease of $-0.14 or -1.82% from the prior close of $7.68. The stock opened at $7.8 and ...

A total of 24 investors have a majority stake in the company with 50% ownership ...

Aug. 13, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...

The company plans to focus its resources on conducting clinical trials for CD388 influenza prevention therapy.

Short interest in Candel Therapeutics Inc (NASDAQ:CADL) increased during the last reporting period, rising from 1.63M to 1.69M. This put 7.65% of the company's publicly available shares short.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ: CADL) reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline resectable ...

Tak, who left in 2018 and is now CEO of Candel Therapeutics Inc., chooses his words carefully when assessing his former ...

Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal ...

JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...